
Loading, please wait...

Loading, please wait...

The TEMPO-2 phase 3 trial randomized 304 adults with early Parkinson's disease to flexible-dose tavapadon 5–15 mg once daily (n=151) or placebo (n=153) for 27 weeks. At week 26, the MDS-UPDRS Parts II and III combined score improved significantly more with tavapadon, with a least-squares mean decrease of 10.3 points versus 1.2 points with placebo (treatment difference −9.1; 95% CI −11.7 to −6.5; P<0.0001). Adverse events occurred in 76% versus 55%, respectively, and were mostly mild to moderate. Nausea (30% vs 3%), headache (17% vs 5%), and dizziness (16% vs 3%) were the most common adverse events.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


The TEMPO-2 phase 3 trial randomized 304 adults with early Parkinson's disease to flexible-dose tavapadon 5–15 mg once daily (n=151) or placebo (n=153) for 27 weeks. At week 26, the MDS-UPDRS Parts II and III combined score improved significantly more with tavapadon, with a least-squares mean decrease of 10.3 points versus 1.2 points with placebo (treatment difference −9.1; 95% CI −11.7 to −6.5; P<0.0001). Adverse events occurred in 76% versus 55%, respectively, and were mostly mild to moderate. Nausea (30% vs 3%), headache (17% vs 5%), and dizziness (16% vs 3%) were the most common adverse events.
2 months ago

Researchers have identified compound 8g, an orally bioavailable corydamine derivative that targets glutathione reductase. By dismantling redox defenses and disrupting NADPH homeostasis, 8g acts synergistically with sorafenib to trigger apoptosis and overcome drug resistance in hepatocellular carcinoma models.
Yesterday

A breakthrough blood test measuring the RNA biomarker Tu-Stroma detects microscopic serous tubal intraepithelial carcinoma (STIC) lesions with remarkable accuracy. This non-invasive diagnostic tool offers crucial biological insight to guide prophylactic surgery decisions for women carrying high-risk genetic mutations.
2 days back

Researchers have engineered novel light-on photoswitchable adrenoceptor agonists targeting β1-receptors. By remaining inactive until illuminated, these precision molecules offer reversible optical control, tailored relaxation kinetics, and distinct efficacy profiles, paving the way for targeted cardiovascular therapies.
2 days back

A single-cell transcriptomic atlas reveals how peripheral nerve injuries cause dorsal root ganglion remodeling. By evaluating proximal nerve crush and resection, researchers identify distinct glial and immune programs that resolve neuropathic pain and promote regeneration.
3 weeks back

A breakthrough study demonstrates that fullerol-primed extracellular vesicles generated in a 3D SECCS bioreactor attenuate ferroptosis and restore myogenic regeneration in diabetes via the FOXO3 pathway, offering a cell-free therapeutic strategy for diabetic musculoskeletal degeneration.
3 weeks back